©TheCanadian Journal ofUrology™: International Supplement, April 2014
83
Petrylak
16.Tannock IF,deWitR,BerryWRetal.Docetaxelplusprednisone
ormitoxantroneplusprednisone foradvancedprostatecancer.
NEngl JMed
2004;351(15):1502-1512.
17.Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M,
Tannock IF. Docetaxel plus prednisone or mitoxantrone plus
prednisone for advancedprostate cancer: updated survival in
theTAX 327 study.
JClinOncol
2008;26(2):242-245.
18.Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and
estramustinecomparedwithmitoxantroneandprednisone for
advancedrefractoryprostatecancer.
NEngl JMed
2004;351(15):
1513-1520.
19.KellyWK, Halabi S, Carducci M et al. Randomized, double-
blind, placebo-controlled phase III trial comparing docetaxel
and prednisone with or without bevacizumab in men with
metastatic castration-resistant prostate cancer: CALGB 90401.
J ClinOncol
2012;30(13):1534-1540.
20.Tannock IF, FizaziK, IvanovSet al.Afliberceptversusplacebo
in combinationwith docetaxel and prednisone for treatment
of men with metastatic castration-resistant prostate cancer
(VENICE): a phase 3, double-blind randomised trial.
Lancet
Oncol
2013;14(8):760-768.
21.QuinnDI,TangenCM,HussainMetal.Docetaxelandatrasentan
versusdocetaxelandplacebo formenwithadvancedcastration-
resistantprostatecancer (SWOGS0421): a randomisedphase3
trial.
LancetOncol
2013;14(9):893-900.
22.Araujo JC,MathewP,ArmstrongAJ et al.Dasatinib combined
withdocetaxel for castration-resistant prostate cancer: results
from aphase 1-2 study.
Cancer
2012;118(1):63-71.
23.Fizazi KS, HiganoCS, Nelson JB et al. Phase III, randomized,
placebo-controlled study of docetaxel in combination with
zibotentan in patients with metastatic castration-resistant
prostate cancer.
JClinOncol
2013;31(14):1740-1747.
24.ScherHI, JiaX, Chi K et al. Randomized, open-label phase III
trialofdocetaxelplushigh-dosecalcitriolversusdocetaxelplus
prednisone forpatientswithcastration-resistantprostatecancer.
J ClinOncol
2011;29(16):2191-2198.
25.VrignaudP, SemiondD, Lejeune P et al. Preclinical antitumor
activityof cabazitaxel, a semisynthetic taxaneactive in taxane-
resistant tumors.
ClinCancerRes
2013;19(11):2973-2983.
26.BisseryMC,BouchardH,Riou JFetal.Preclinicalevaluationof
TXD258, anew taxoid. Proceedingof the 91
st
AnnualMeeting
of the American Association for Cancer Research. 2000:
Abstract 1364.
27.Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new
taxane for metastatic castrate-resistant prostate cancer?
ClinCancerRes
2012;18(24):6574-6579.
28.de Bono JS, Oudard S, OzgurogluM et al. Prednisone plus
cabazitaxel ormitoxantrone formetastatic castration-resistant
prostate cancer progressing after docetaxel treatment:
arandomisedopen-label trial.
Lancet
2010;376(9747):1147-1154.
29.BracardaS,GernoneA,GasparroDetal.Real-worldcabazitaxel
safety: the Italianearly-accessprogram inmetastaticcastration-
resistant prostate cancer.
FutureOncol
2013Dec 3. Epubahead
of print.
30.Basch E, Autio K, Ryan CJ et al. Abiraterone acetate plus
prednisone versus prednisone alone in chemotherapy-naive
menwithmetastaticcastration-resistantprostatecancer:patient-
reportedoutcome results of a randomisedphase3 trial.
Lancet
Oncol
2013;14(12):1193-1199.
31.ParkerC,NilssonS,HeinrichDetal.Alphaemitterradium-223
and survival inmetastatic prostate cancer.
NEngl JMed
2013;
369(3):213-223.
32.Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T
immunotherapy for castration-resistant prostate cancer.
NEngl JMed
2010;363(5):411-422.
33.KirbyBJ, JodariM,LoftusMSetal.Functional characterization
of circulating tumor cells with a prostate-cancer-specific
microfluidicdevice.
PloSOne
2012;7(4):e35976.
34.Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH.
Docetaxel down-regulates the expression of androgen
receptorandprostate-specificantigenbutnotprostate-specific
membraneantigen inprostatecancercell lines: implications for
PSAsurrogacy.
Prostate
20091;69(14):1579-1585.
35.Pond GR, Armstrong AJ, Galsky MD, Wood BA, Leopold
L, Sonpavde G. Efficacy of docetaxel-based chemotherapy
following ketoconazole in metastatic castration-resistant
prostatecancer: implications forprior therapy inclinical trials.
UrolOncol
2013;31(8):1457-1463.
36.PezaroCJ,OmlinAG,AltavillaAet al.Activityof cabazitaxel in
castration-resistant prostate cancer progressing after docetaxel
and next-generation endocrine agents.
Eur Urol
2013 Dec 17.
Epubaheadofprint.
